QPPV.COM KNOWLEDGE ASSESSMENT

Axatilimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Axatilimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 When documenting a suspected infection in a patient receiving axatilimab, which information most directly supports assessment of the event?

Suspected or confirmed pathogen, infection site, severity, treatment, recurrence, and any treatment interruption The patient’s response rate alone, without infection details Only the date axatilimab was first prescribed Only whether the patient has ever received a transplant

Question 2 of 10 A regulatory team is preparing materials for a jurisdiction outside the United States. What is the most appropriate use of the article’s indication information?

Treat it as a description of the U.S. indication and verify the applicable local authorisation and product information Assume that FDA authorisation automatically establishes the same indication in every jurisdiction Apply the U.S. indication only if the local product has the same brand name Use the U.S. indication as a substitute for checking local reporting and prescribing requirements

Question 3 of 10 The U.S. label reports treatment-emergent anti-drug antibodies in a proportion of tested patients, without a reported clinically meaningful effect on pharmacokinetics, pharmacodynamics, or effectiveness. What is the best interpretation?

Immunogenicity is a characterised product property, but an individual loss of response cannot be assumed to be antibody-mediated Any patient with a loss of response should be considered to have neutralising antibodies The reported antibody frequency proves that treatment is ineffective in most patients The label findings establish that anti-drug antibodies never occur

Question 4 of 10 Which regimen matches the U.S. recommended dose described in the article for patients who meet the weight criterion?

0.3 mg/kg intravenously, capped at 35 mg, over 30 minutes every two weeks 0.3 mg/kg subcutaneously, with no maximum dose, once every month 35 mg intravenously over 30 minutes every week, regardless of body weight 0.3 mg/kg orally every two weeks until a complete response occurs

Question 5 of 10 In the label-evaluable cohort receiving the recommended dose, what does the reported 75% overall response rate represent?

The proportion with complete or partial response under the specified NIH criteria through Cycle 7 Day 1 The proportion cured of cGVHD by the end of the study The proportion who survived longer than patients receiving standard therapy The proportion who had a complete response at the first assessment

Question 6 of 10 What is the appropriate reporting principle for a serious suspected adverse reaction in routine pharmacovigilance practice?

Report through the applicable local system and follow current product information and jurisdictional requirements Report only if causality has been conclusively proven Use the U.S. reporting pathway in every jurisdiction Wait for an aggregate review before taking any required reporting action

Question 7 of 10 Which approach is most appropriate when assessing an event common in the underlying cGVHD population?

Avoid defaulting to ‘not related’; assess the clinical context, alternative causes, exposure pattern, and available dechallenge or rechallenge information Classify it as unrelated because the event is common in cGVHD Classify it as product-related solely because it occurred during treatment Exclude it from review unless it led to permanent discontinuation

Question 8 of 10 Under the U.S. prescribing information described, which general principle governs how long treatment continues?

Treatment continues until progression or unacceptable toxicity, with dose decisions guided by the label and treating team Treatment must stop as soon as any partial response is recorded Treatment continues for a fixed seven cycles in every patient Treatment continues indefinitely, even after progression or unacceptable toxicity

Question 9 of 10 How should the reported 44% rate of serious adverse reactions in the label safety cohort be used in pharmacovigilance interpretation?

As a descriptive frequency in that selected clinical-trial population, not as a comparative rate against other cGVHD therapies As proof that axatilimab causes serious reactions more often than every alternative treatment As an estimate of the rate in all patients who may receive axatilimab in any jurisdiction As evidence that each serious event in the cohort was caused by axatilimab

Question 10 of 10 Which description best captures axatilimab’s pharmacological classification and principal target?

A humanised monoclonal antibody that blocks CSF-1R A small-molecule inhibitor that blocks donor T-cell activation An antibody–drug conjugate that delivers a cytotoxic payload to macrophages A lymphocyte-depleting antibody directed against a T-cell surface marker

QPPV.com

Axatilimab: Classification, Mechanism, Clinical Evidence and Pharmacovigilance — Knowledge Assessment

Cookie Settings